The purpose of this study was to assess the feasibility and efficacy of a treatment regimen for pediatric acute myelogenous leukemia (AML) that uses four rotating drug pairs and adjusts dosages of etoposide and cytarabine to target specific plasma concentrations. Thirty-one girls and 27 boys (median age, 9.7 years) with de novo AML were treated on the protocol. Six cycles of chemotherapy were planned. Cycles 1 to 4 comprised the drug combinations cytarabine plus etoposide, cytarabine plus daunomycin, etoposide plus amsacrine, and etoposide plus azacitidine, respectively. For cycles 5 and 6, the first two combinations were repeated. Dosages were adjusted to achieve plasma concentrations of 1.0 M ± 0.1 M cytarabine and 30 M ± 0.3 M etoposide. Forty-four patients (76%) entered complete remission. Of those, 24 have had relapses; 23 remain alive in first or subsequent remission. The 5-year event-free survival (EFS) estimate was 31.0% ± 5.9%; the 5-year survival estimate was 41.4% ± 6.3%. Six patients (10%) died of the toxic effects of therapy. Severe neutropenia occurred in all cycles. Long-term complications of therapy included hepatitis C, cardiac insufficiency, and hearing loss. Adjustment of cytarabine and etoposide dosage was feasible for achieving targeted plasma drug concentrations; however, the potential clinical efficacy of this approach was offset by substantial acute and long-term toxicity. Leukemia (2000) 14, 1736-1742.
Introduction
The prospect of long-term survival for children with acute myelogenous leukemia (AML) remains relatively poor. 1 Although more than 80% of these children achieve complete remission on contemporary intensive chemotherapy regimens, only about 50% are likely to be cured. 2, 3 Primary or secondary resistance to chemotherapy remains the most common cause of treatment failure. A number of studies have found that intensification of chemotherapy during induction and consolidation phases improves outcomes. [4] [5] [6] [7] Cytarabine (Ara-C), anthracyclines, and etoposide (VP-16) are often used to treat AML. However, the pharmacokinetic disposition of these agents in children can vary extensively. 8, 9 Patients who clear these drugs rapidly may have inadequate systemic exposure that results in treatment failure. Conversely, patients who eliminate these agents slowly are at greater risk of life-threatening toxicity. With the aim of eliminating interpatient variability in exposure to Ara-C and VP- 16 used pharmacokinetic methods to individualize the dosages of these drugs in each course in which they were given. Here we address the feasibility of incorporating this individualized dosage adjustment method into a treatment plan for children with AML and assess the short-term and long-term consequences of this strategy.
Patients and methods

Patients
Between April 1987 and March 1991, 67 patients were enrolled on the AML-87 protocol. Fifty-eight were previously untreated patients with de novo AML, six patients had secondary AML, and two patients had myelodysplastic syndrome. The remaining patient was found upon subsequent review to have acute lymphoblastic leukemia and was reassigned to the appropriate treatment protocol. Standard morphologic, cytochemical, and immunophenotypic 10 criteria were used to establish the diagnosis and classification of AML according to the French-American-British (FAB) system. 11 Cytogenetic studies of all patients' malignant cells were conducted. The institutional review board of St Jude Children's Research Hospital approved all investigations. Written informed consent was obtained from patients, parents, or guardians, as appropriate.
Treatment plan
Remission induction therapy consisted of three cycles of chemotherapy with four agents. In cycle 1, Ara-C was administered as a 96-h continuous subcutaneous infusion at an initial dosage of 500 mg/m 2 per day. The dosage was adjusted as described below to achieve a targeted plasma concentration. Concurrently, VP-16 was administered intravenously: a loading dose of 70 mg/m 2 given over 1 h was followed by a 96-h infusion at an initial dosage of 500 mg/m 2 per day; the dosage was adjusted as described below. In cycle 2, Ara-C was administered as in cycle 1, but over a period of 120 h. A bolus infusion of daunomycin (50 mg/m 2 ) was administered on days 1 and 2. In cycle 3, VP-16 was administered as in cycle 1, and amsacrine (m-AMSA; 125 mg/m 2 per day) was administered as a continuous 72-h intravenous infusion ( Figure 1 ). Cycles 2 and 3 were begun as soon as hematopoietic recovery was adequate (absolute neutrophil count Ͼ0.5 × 10 9 /l and platelet count Ͼ75 × 10 9 /l) and gastrointestinal and infection complications had resolved, but were begun without these requirements in the case of persistent marrow infiltration or progressive disease. Consolidation ther- apy consisted of three additional cycles of combination chemotherapy. In cycle 4, VP-16 was administered as in cycle 1, and bolus intravenous infusions of 5-azacytidine (5-AZ; 300 mg/m 2 ) were given 24 and 48 h after completion of the VP-16 infusion. Cycle 5 was identical to cycle 2, and cycle 6 was identical to cycle 1. No maintenance chemotherapy was used in this protocol. All-trans retinoic acid was not used for patients with acute promyelocytic leukemia.
Patients with no evidence of central nervous system (CNS) leukemia received five courses of triple intrathecal therapy (methotrexate, hydrocortisone, and Ara-C (MHA)) adjusted for age. 12 One course was given with each cycle of systemic therapy, starting with cycle 2. Children who had CNS involvement at the time of diagnosis were treated with the intrathecal regimen weekly for at least 4 weeks or until the CSF was clear, and then with each cycle of systemic therapy. Patients with CNS involvement who remained in complete remission received cranial irradiation (24 cGy) after the completion of chemotherapy.
Complete response (CR) was defined as the complete disappearance of measurable disease, restored bone marrow function, and normal clinical performance status.
Complications of treatment and supportive care
Complications of treatment were detected and evaluated as follows: hearing loss and speech delay by audiometry; cardiac dysfunction by clinical cardiovascular examination, diagnostic imaging (echocardiography, chest radiography), or electrocardiography; clinical neurological disorder (seizure) by electroencephalography or diagnostic imaging; endocrine dysfunction by weight above the 97th percentile (obesity), and by laboratory tests of thyroid function, serum gonadotropin, androgen, estrogen, and hormone stimulation or suppression; learning disabilities by neuropsychological evaluation of global intellect and academic achievement; and cataracts by ophthalmologic examination.
Supportive care was available as needed and included the best medical management of hemorrhage, infection, weight loss, or disseminated intravascular coagulation. Patients with mucositis received platelet transfusions to maintain a platelet count Ͼ20 000/l. Trimethoprim-sulfamethoxazole chemotherapy was begun on day 14 of induction for prophylaxis of Pneumocystis carinii pneumonitis. Fevers accompanied by neutropenia were treated with triple broad-spectrum antibiotics; amphotericin B was routinely added if fever persisted. Hematopoietic colony-stimulating factors were not used in Leukemia this study. All patients were treated in rooms with positivepressure high-efficiency particulate air (HEPA) filtration units.
Pharmacokinetic studies and dosage adjustment
In cycle 1, plasma samples were obtained 1, 6 , and 24 h after the beginning of the Ara-C and VP-16 infusions for measurement of plasma drug concentrations; samples were obtained subsequently as needed for dosage adjustment. Plasma drug concentrations were assayed by high-performance liquid chromatography (HPLC) as previously described;
13,14 ultraviolet absorbance was used to detect Ara-C, and electrochemical detection was used to detect VP-16. The inter-day coefficient of variation was consistently less than 3.6% for the Ara-C assay and less than 7.1% for the VP-16 assay.
Samples collected at hours 1 and 6 were immediately assayed. Dosage adjustment was based on plasma concentrations at hour 6. If the drug concentration fell within 10% of the targeted concentration (0.9 to 1.1 M for Ara-C and 27 to 33 M for VP-16), no dosage adjustment was made. If the plasma concentration was outside this range, the dosage was adjusted proportionally to achieve the targeted concentration (for example, if a VP-16 dosage of 500 mg/m 2 per day produced a plasma concentration of 40 M, the dosage was adjusted to 375 mg/m 2 per day to target a concentration of 30 M). Assays of plasma samples obtained after hour 6 were used to assess the efficacy of the targeting strategy. Subsequent cycles began at the dosage last administered in the previous cycle, and plasma samples were obtained as needed for dosage adjustment. Ara-C apparent clearance and VP-16 plasma clearance rates were calculated for patients whose steadystate plasma drug concentrations were measured after dose adjustment. VP-16 clearance was calculated as
where k 0 is the final infusion rate and C ss is the steady-state plasma concentration. Because Ara-C was administered as a subcutaneous, 15 rather than an intravenous infusion, apparent clearance was calculated as
where F is bioavailability, k 0 is the final infusion rate, and C ss is the steady-state plasma concentration.
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Statistical analysis
The duration of event-free survival was measured as the interval between study entry and the first adverse event (relapse, withdrawal from the study, or death from any cause) or the most recent follow-up examination. Patients who did not have a CR were assigned an EFS value of zero. The duration of survival was measured as the interval between entry on the study and either the last follow-up examination or death. Distributions of survival rates and EFS rates were estimated by the method of Kaplan and Meier 16 and were compared by using the Mantel-Haenszel statistic. All estimates of outcome are reported within (±) one standard error (s.e.). Fisher's exact test was used to determine whether an association existed between the rate of CR and the presence of defined risk factors.
To assess the association between plasma drug clearance and toxicity, we used Student's t-test to compare the average clearance of Ara-C and of VP-16 in two groups of patients (those who experienced fewer than five episodes of grade 3 or 4 toxicity and those who experienced five or more episodes). We also examined the association between these two groups and the dosages of Ara-C (Ͻ500 or у500 mg/m 2 per day) and VP-16 (Ͻ500 or у500 mg/m 2 per day) by using Fisher's exact test. Student's t-test was used to compare the average number of episodes of grade 3 or 4 toxicity experienced by patients who received Ͻ500 and у500 mg/m 2 per day of Ara-C and of VP-16. All comparisons were considered significant at a type I error rate of ϰ = 0.05, and all P values reported reflect two-sided tests. All statistical analyses used SAS Release 6.12 software (SAS, Cary, NC, USA).
Results
Patients
The median age at diagnosis of the 27 boys and 31 girls with de novo AML was 9.7 years (range, 0.5 to 20.7 years). At the time of diagnosis, the median WBC count was 13.8 × 10 9 /l (range, 1.0 to 249 × 10 9 /l), the median hemoglobin concentration was 82 g/l (range, 32 to 161 g/l), and the median platelet count was 49 × 10 9 /l (range, 5 to 547 × 10 9 /l). The FAB AML subtypes, in order of frequency, were M2 (38%), M5 (19%), M3 (12%), M7 (10%), M1 (10%), M4 (8.6%), and M0 (1.7%). Cytogenetic abnormalities were present in 82.8% of the cases: t(8;21) in 24.1%, inv(16) in 8.6%, t(15;17) in 10.3%, t(9;11) in 5.2%, other 11q23 abnormalities in 6.9%, and miscellaneous karyotypic structural changes in 22.4% of cases. Numerical chromosome changes included +21 (3.4%) and −7 (1.7%).
Pharmacokinetic studies
Fifty-eight patients were included in the pharmacokinetic analysis ( Table 1 ). The median Ara-C dosage required to achieve a plasma concentration of 1 M ± 0. 
Outcome
Nine of the 67 patients enrolled on the study (six with secondary AML, two with MDS, and one who was misdiagnosed) were excluded from the outcome analysis. Of the 58 patients with de novo AML, two withdrew from the study because of excessive toxicity; one of these patients received only one cycle of induction chemotherapy, and one received only two cycles. These two patients were included in the event-free survival analysis as having experienced an adverse event at the time they withdrew from the study. However, both remain free of disease, 9 years after the diagnosis of AML. Seventy-six percent of the patients (44 of 58) had a complete response to
Figure 2
Survival estimates of children with de novo AML enrolled on the AML-87 study.
therapy. Twenty-three (52%) had a CR after the first course (Ara-C plus VP-16), 19 after the second course (Ara-C plus daunomycin), and one after the third course (VP-16 plus m-AMSA). One patient had a complete response only after the fourth course (VP-16 plus 5-AZ). Of the 14 patients who did not enter remission during treatment on the AML-87 protocol, only one remains alive, 10 years after diagnosis; this patient had a subsequent response to higher-dose Ara-C. Twenty-four patients experienced hematologic relapse after achieving a CR. Of those, five remain alive after receiving high-dose chemotherapy followed by hematopoietic stem cell transplantation (HSCT); the remaining 19 patients died after salvage chemotherapy, HSCT, or both. Six patients died during remission from complications of therapy and one died during remission as the result of an automobile accident. At a median follow-up of 6.4 years (range, 1 to 12 years), 23 patients remain alive with no evidence of disease. Of the nine patients who underwent HSCT because of resistant or recurrent disease, six remain alive. Figure 2 shows estimates of survival for all patients enrolled on the AML87 study. The overall survival estimate at 5 years and at 10 years was 41.4% ± 6.3% and 41.4% ± 11.2%, respectively. Table 2 summarizes the severe (grade 3 or 4) toxic effects observed in each cycle of chemotherapy. Severe myelosup- Table 2 Toxic effects according to cycle of chemotherapy on the AML-87 protocol Leukemia pression occurred in all of the 288 cycles of chemotherapy administered. Myelosuppression was most severe during cycles 1 and 6, which combined Ara-C with VP-16. Gastrointestinal toxicity, mainly mucositis, occurred in 136 cycles (47.2%), and was most frequently seen in cycle 1. Severe infectious complications (documented infections with systemic inflammatory response) were noted in 108 cycles (37.5%) and were most frequent in cycle 5. Hepatotoxicity (increased bilirubin concentration, elevated transaminase activity, or both) occurred in 82 cycles (28%). This complication was most frequent in cycles 1 (35%) and 2 (21%); in the other cycles, only 7% to 15% of patients were affected. VP-16 with m-AMSA (cycle 3) was the best-tolerated combination. Nausea and vomiting or diarrhea that necessitated inpatient care were infrequent (11 cycles; 4%). Severe skin manifestations, including rash, peeling, blistering, and desquamation, were noted in 14 cycles (5%), predominantly cycles 1 and 6 (Ara-C plus VP-16). Neurologic toxicity (seizures that resolved with medical treatment) occurred in three patients. There was no association between toxicity and the rate of clearance of VP-16 (P = 0.57) or Ara-C (P = 0.84). Grade 3 and 4 toxicity was equally prevalent among patients who received more than and patients who received less than 500 mg/m 2 per day of Ara-C or VP-16. Treatment-associated complications often delayed the start of subsequent cycles of chemotherapy during induction. The median time between the beginning of the first and second courses was 27 days (range, 13 to 56 days), and a median of 34 days (range, 19 to 103 days) elapsed between the second and third courses.
Toxicity
Patients were considered to be long-term survivors 10 years after completion of therapy. There were 23 long-term survivors at the time of this analysis. The late complications seen in this group are summarized in Table 3 . The incidence of endocrine abnormalities, including ovarian failure, growth hormone deficiency, and hypothyroidism, was higher among patients who underwent allogenic HSCT, all of whom underwent total body irradiation as part of the preparatory regimen. Only one patient, who underwent hematopoietic stem cell transplantation, had symptomatic heart failure; four patients had asymptomatic abnormally low shortening fraction. Hepatitis C infection with chronic liver disease was noted in four patients who underwent chemotherapy alone and in one who underwent autologous HSCT. Three patients who underwent chemotherapy alone had sensorineural hearing loss. Cataracts were found in one patient who underwent allogeneic HSCT. 
Discussion
The AML-87 treatment protocol was designed to reduce the variability of systemic drug exposure among patients, and thus to increase the efficacy of therapy, by individualizing Ara-C and VP-16 doses to achieve predetermined steady-state plasma concentrations. This approach had been shown to produce more consistent dose intensity than does the use of standardized dosage based on body surface area. 9 Although no direct correlation has been found between plasma concentration of Ara-C and intracellular concentration of Ara-CTP, its active metabolite, low plasma exposure may limit Ara-CTP accumulation, 15, 17 whereas high plasma levels may cause unnecessary toxicity. The targeted Ara-C plasma concentration, 1.0 M, was selected on the basis of data suggesting that it would result in an effective intracellular Ara-CTP concentration. 15, 18, 19 The targeted VP-16 concentration, 30 M, was selected to produce a total leukemic cell and systemic exposure similar to that reported to be effective in several studies. 20, 21 Severely myelosuppressive chemotherapy during the initial phase of treatment appears to be crucial for long-term diseasefree survival in AML. 4, 22 Early intensification of induction therapy is based on in vitro evidence that leukemic cells are recruited into the cell cycle 6 to 10 days after initial exposure to cytotoxic agents 23 or on the theory (Goldie-Coldman hypothesis) that the initial therapy selects for resistant leukemic clones that arise by spontaneous mutation. 24 These theoretical assumptions have guided several studies. Investigators from the Children's Cancer Group randomly assigned patients to receive five-drug induction chemotherapy either on a predetermined schedule (all drugs given on days 0-4 and 10-14) or on a flexible schedule (on days 0-4 and 14-18 or later, depending on the patient's response). Outcome was significantly better for the patients whose chemotherapy was not delayed (3-year EFS estimate, 42% vs 27%). 2 Using a similar strategy, St Jude investigators tested the value of early intensification of induction therapy with a regimen that combined five drugs given in three cycles: Ara-C plus VP-16; Ara-C, daunomycin, and thioguanine; and VP-16 plus 5-AZ. Successive cycles were started immediately (on day 10 of the first cycle) in the absence of severe bone marrow hypoplasia. Although the rate of remission induction was high (85%), the 2-year event-free survival estimate was only 33%. Disease recurrence was the primary cause of treatment failure. 25 German and English investigators have used alternative early-intensification approaches in which Ara-C, daunomycin, VP-16, and thioguanine combinations are administered at variable intervals, depending on the patient's response. 3, 26 Rates of remission and estimates of survival and EFS were comparable to those obtained by the most successful early intensification treatment approaches. 2 We reasoned that some of the disparities observed in the results of early intensification studies were caused by variable individual drug disposition. A strategy that could ensure the achievement of a predetermined plasma drug concentration should enhance the effectiveness of early treatment intensification by ensuring adequate systemic exposure for patients whose rate of drug clearance is high. Such a strategy should also reduce the severity of toxicity for patients whose clearance rates are low. Like previous studies, our analysis demonstrated great variability among patients in the plasma pharmacokinetics of Ara-C and VP-16; 27 apparent clearance rates of Ara-C varied by 20-fold, and clearance rates of VP-16 by eight-fold. 28 By adjusting the dosages of these drugs on the basis of plasma concentration at hour 6 of the infusion, we were able to achieve plasma concentrations within 10% of the targeted values. Median steady-state plasma drug concentrations were within the targeted range 6 h after dosage adjustment, a finding indicating that this strategy is feasible. However, disease control was not improved. The complete response rate of 76% was not superior to the rates obtained in other trials employing alternative approaches. 2, 3, 29, 30 It is not clear why this approach did not improve patient outcomes. We considered two possible explanations. First, the use of dose-intensive VP-16 with Ara-C might have caused severe toxicity without adding substantially to the overall treatment efficacy. Gastrointestinal toxicity or severe infection, which affected almost 80% of patients during the first course of induction chemotherapy, often delayed subsequent courses. However, although the estimated 5-year EFS rate was higher for patients whose second induction course began within 30 days after the beginning of the first course (35% ± 7.6%) than for other patients (25% ± 8.8%), this difference was not found to be statistically significant. The second possibility is that the regimen acted selectively. In a previous study, a regimen using targeted systemic drug exposure improved outcomes for patients with B-lineage, but not T-lineage, acute lymphoblastic leukemia. 9 In our study, outcomes may have differed among subsets of patients, obscuring the effect of more consistent systemic exposure. However, the study lacked sufficient statistical power to identify prognostic factors correlated with response to therapy.
Toxicity was not related to the rate of clearance of Ara-C or VP-16 or to dosages of either drug greater than 500 mg/m 2 per day. Individual adjustment of the Ara-C and VP-16 dosage is likely to have minimized any extremes of plasma drug concentration caused by rapid or slow drug clearance. Severe myelosuppression, gastrointestinal toxicity, and rash were most frequent in cycles that combined Ara-C with VP-16, a finding suggesting that the targeted concentrations chosen may have been too high for this combination therapy. However, the rate of mortality during the first month of induction therapy (3.4%) was lower than the rates reported for other regimens. 2 Because fewer patients had dosage adjustments after cycle 1, we were unable to compare steady-state drug concentration across cycles. Steady-state concentrations in later cycles may have been less well controlled than those in cycle 1 were shown to be.
The late effects of the AML-87 treatment protocol were assessed in patients who survived more than 10 years after diagnosis. Among those who underwent HSCT, the long-term sequelae were those associated with total-body irradiation. 31 The high incidence of hepatitis C-induced chronic liver disease was presumably caused by extensive blood product support at a time when reliable hepatitis C screening was unavailable. Obesity, a well known complication of antileukemia treatment in acute lymphoblastic leukemia, 32 was observed in 30% of the survivors. Many also had hearing loss of the sensorineural type, probably caused by ototoxic antibiotics used to treat infectious complications. Because of the relatively low cumulative dose of anthracycline, symptomatic cardiac dysfunction was not a problem among our patients.
We have demonstrated that individualized dosages of Ara-C and VP-16 can produce more consistent systemic drug exposure among patients, thus effectively standardizing the systemic dose intensity of therapy. However, this multiagent regimen caused severe toxicity, and its long-term efficacy was inferior to some of the regimens 2, 3, 33 that use traditional methods of dosage determination.
